ZEN003694 Continuation for Prostate Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial continues to provide ZEN003694 to patients who have already shown improvement from it in an earlier study. The medication helps by changing certain body functions related to their condition. Patients must have been part of an earlier study with this medication to join this continuation trial.
Do I need to stop my current medications for this trial?
The trial does not specify if you need to stop taking your current medications, but it does not allow changes to your current treatment for the cancer being studied.
Is ZEN003694 (Enzalutamide) safe for humans?
What data supports the effectiveness of the drug enzalutamide for prostate cancer?
Are You a Good Fit for This Trial?
This trial is for prostate cancer patients who saw benefits from a previous ZEN003694 study. They should be in good physical condition (ECOG status of 0 or 1) and have handled the drug well before. Participants must start this follow-up within two weeks after their last dose in the original trial, unless given more time by the sponsor.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Continuation Treatment
Participants continue to receive ZEN003694 in combination with enzalutamide after completing the parent protocol
Follow-up
Participants are monitored for safety and effectiveness after continuation treatment
What Are the Treatments Tested in This Trial?
Interventions
- Enzalutamide
- ZEN003694
Find a Clinic Near You
Who Is Running the Clinical Trial?
Zenith Epigenetics
Lead Sponsor